Allogene Therapeutics, Inc. Shareholders' Equity
Allogene Therapeutics, Inc. (ALLO) had Shareholders' Equity of $436.18 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $436.18M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $278.88M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $292.54M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $315.33M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $436.18M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $278.88M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $292.54M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $315.33M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $344.56M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $385.39M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $422.18M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $463.75M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $515.04M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $461.37M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $512.23M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $580.63M 10-Q · filed 2024-11-07 | $583.10M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $621.41M 10-Q · filed 2024-11-07 | $622.91M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $592.01M 10-Q · filed 2024-11-07 | $592.26M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $666.88M 10-K · filed 2025-03-13 | $665.87M 10-K · filed 2023-02-28 |
| 2022-09-30 | $743.40M 10-K · filed 2024-03-14 | $739.96M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $806.48M 10-K · filed 2024-03-14 | $801.95M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $865.27M 10-K · filed 2024-03-14 | $855.23M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $925.20M 10-K/A · filed 2024-03-14 | $916.41M 10-K · filed 2022-02-23 |
| 2021-09-30 | $969.94M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $1.02B 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $1.07B 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $1.01B 10-K/A · filed 2024-03-14 | $1.08B 10-K · filed 2021-02-25 |
| 2020-09-30 | $1.12B 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.16B 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $606.52M 10-Q · filed 2021-08-04 | |
| 2019-12-31 | $629.02M 10-K/A · filed 2024-03-14 | |
| 2019-09-30 | $619.72M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $655.63M 10-Q · filed 2020-11-04 | |
| 2019-03-31 | $681.23M 10-Q · filed 2020-08-05 | |
| 2018-12-31 | $703.16M 10-K · filed 2022-02-23 | |
| 2018-09-30 | -$168.44M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | -$129.44M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | -$2.59M 10-Q · filed 2019-08-07 | |
| 2017-12-31 | -$2.00K 10-K · filed 2021-02-25 | |
| 2017-11-29 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |